Castle Creek Biosciences, Inc. is a clinical-stage cell and gene therapy company. The Company is focused on developing and commercializing disease-modifying therapies for patients suffering from rare diseases affecting the skin and connective tissue. The Company's autologous fibroblast platform serves as the foundation for developing personalized, targeted and redosable cell-based gene therapy product candidates for both monogenic and chronic disorders. Its lead product candidate, dabocemagene autoficel (D-Fi), is in a Phase III clinical trial for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). D-Fi is a disease-modifying autologous cell-based gene therapy, developed to address the deficiency of functional type VII collagen protein (COL7) in patients with autosomally recessive or dominant dystrophic epidermolysis bullosa (DEB). The Company is also developing a second product candidate, FCX-013, for the treatment of moderate to severe localized scleroderma.